AC Immune SA
NASDAQ:ACIU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AC Immune SA
Accumulated Depreciation
AC Immune SA
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AC Immune SA
NASDAQ:ACIU
|
Accumulated Depreciation
-CHf13.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-22%
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Accumulated Depreciation
-$91.1m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-98%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Accumulated Depreciation
-CHf11.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Accumulated Depreciation
-CHf148.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Accumulated Depreciation
-CHf2.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
AC Immune SA
Glance View
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
See Also
What is AC Immune SA's Accumulated Depreciation?
Accumulated Depreciation
-13.7m
CHF
Based on the financial report for Dec 31, 2025, AC Immune SA's Accumulated Depreciation amounts to -13.7m CHF.
What is AC Immune SA's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 10Y
-22%
Over the last year, the Accumulated Depreciation growth was -10%. The average annual Accumulated Depreciation growth rates for AC Immune SA have been -14% over the past three years , -19% over the past five years , and -22% over the past ten years .
